Drug development – Page 8

Prototype not scalable during IND/NDA filing – preventing late-stage reformulation

Addressing Scalability Challenges During IND/NDA Filings to Prevent Late-Stage Reformulation As pharmaceutical professionals engaged in formulation and process development, encountering a prototype not scalable during IND/NDA filing stages is a…

Bioavailability risk flagged during regulatory review – regulatory expectations for formulation data

Managing Bioavailability Risks Identified During Regulatory Review: A Comprehensive Playbook In the pharmaceutical manufacturing landscape, the identification of bioavailability risks during regulatory review can pose significant challenges for formulation development…

Prototype not scalable during scale-up preparation – regulatory expectations for formulation data

Tackling Scalability Issues in Formulation Development: An Actionable Playbook In the realm of pharmaceutical manufacturing, the transition from prototype to scalable production can often present unforeseen challenges. A failure to…

Formulation fails stability targets during scale-up preparation – CMC risk assessment and mitigation

Mitigating Risks When Formulation Fails Stability Targets During Scale-Up Preparation In pharmaceutical development, the transition from small-scale formulation to large-scale production is fraught with risk. One of the most critical…

Dissolution variability unexplained during IND/NDA filing – CMC risk assessment and mitigation

Addressing Unexplained Dissolution Variability During IND/NDA Filing: A Comprehensive Playbook Dissolution variability during the Investigational New Drug (IND) and New Drug Application (NDA) filing can lead to significant delays, regulatory…

QbD elements missing during regulatory review – how to redesign formulation strategy

Identifying Missing QbD Elements During Regulatory Review and Redesigning Formulation Strategy In the pharmaceutical sector, the absence of Quality by Design (QbD) elements during regulatory reviews can lead to significant…

Excipient incompatibility identified late during scale-up preparation – how to redesign formulation strategy

Strategies for Addressing Late-Stage Excipient Incompatibility in Formulation Development During the critical phase of scale-up preparation, pharmaceutical development teams may encounter excipient incompatibility issues, which can severely impact timelines and…

Data reproducibility concerns during inspection support – method validation strategy

Addressing Data Reproducibility Concerns During Method Validation in Pharmaceutical Inspections In the pharmaceutical manufacturing landscape, reproducibility of data is paramount, especially during inspections that evaluate compliance with regulatory standards. Data…

Tag: Drug development

Prototype not scalable during IND/NDA filing – preventing late-stage reformulation

Bioavailability risk flagged during regulatory review – regulatory expectations for formulation data

Prototype not scalable during scale-up preparation – regulatory expectations for formulation data

Formulation fails stability targets during scale-up preparation – CMC risk assessment and mitigation

Dissolution variability unexplained during IND/NDA filing – CMC risk assessment and mitigation

QbD elements missing during regulatory review – how to redesign formulation strategy

Excipient incompatibility identified late during scale-up preparation – how to redesign formulation strategy

Data reproducibility concerns during inspection support – method validation strategy

Method robustness questioned during early development – scientific rigor regulators expect

Data reproducibility concerns during tech transfer preparation – risk-based methodology optimization

Data reproducibility concerns during scale-up readiness – preventing downstream development failure

Experimental bias identified during early development – risk-based methodology optimization